Protara Therapeutics (TARA) Long-Term Deferred Tax (2013 - 2023)

Protara Therapeutics (TARA) has reported Long-Term Deferred Tax for 7 consecutive years, with $54.3 million the latest figure, recorded in Q4 2023.

• In Q4 2023, Long-Term Deferred Tax rose 3574.22% year-over-year to $54.3 million; the TTM figure through Dec 2023 stood at $54.3 million (up 3574.22% YoY), while the FY2023 annual figure was $54.3 million, up 3574.22% from the prior year.
• Long-Term Deferred Tax rose to $54.3 million in Q4 2023 per TARA's latest filing, from $1.5 million in the prior quarter.
• Across five years, Long-Term Deferred Tax topped out at $54.3 million in Q4 2023 and bottomed at $322000.0 in Q4 2020.
• Historically, Long-Term Deferred Tax has averaged $16.7 million across 5 years, with a median of $4.2 million in 2019.
• Annual changes were most pronounced in 2021 — Long-Term Deferred Tax soared 7151.55% — and 2022, when it tumbled 93.67%.
• Protara Therapeutics' Long-Term Deferred Tax stood at $4.2 million in 2019, then tumbled by 92.29% to $322000.0 in 2020, then jumped by 7151.55% to $23.3 million in 2021, then sank by 93.67% to $1.5 million in 2022, then jumped by 3574.22% to $54.3 million in 2023.
• Business Quant data shows TARA's Long-Term Deferred Tax at $54.3 million in Q4 2023, $1.5 million in Q4 2022, and $23.3 million in Q4 2021.